Joanna Mitri , chief medical officer at Sequel Med Tech Dr
Competing interests PG has received occasional fees, either personally or institutionally, for the activities of speaking, scientific advising, or clinical research from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk, Organon, Pfizer, and Sanofi
Dehydration is a common concern for patients on GLP-1 medication, since reduced appetite naturally leads to drinking less
A patient carrying specific GLP1R variants may benefit from earlier dose escalation, while someone with FTO-risk alleles might experience faster initial appetite suppression